Hopec Pharma pioneers the first intravesical bacterial immunotherapy for high-grade non-muscle-invasive bladder cancer. Our proprietary genetically-engineered *E. coli* platform delivers targeted immune activation directly to tumors, bypassing systemic toxicity. This breakthrough approach transforms the bladder's microenvironment into an anti-cancer immune fortress, offering superior efficacy over current BCG and chemotherapy standards while enabling powerful combination therapy potential.